Clinical Trial Update: Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing immunogenicity and safety of an inactivated COVID-19 vaccine in adults, including those with HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• China National Biotec Group Company Limited inactivated COVID-19 vaccine (inactivated COVID-19 vaccine)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: HIV Infections, COVID-19 | Phase 4 | Status: UNKNOWN